| 1 |
Lead selection of allergen non.binding hybrid immunoglobulin E for the treatment of allergic severe asthma |
| Antibody |
Asthma |
FcεRIα |
Lead |
FatiAbGen Co., Ltd. |
RS-2023-00284138 |
|
| 2 |
Development of innovative therapeutics that dually protect against bone erosion and inflammatory arthritis |
| Antibody |
Rheumatoid Arthritis |
Integrin αvβ3/Siglec.15 |
Preclinical |
MedPacto, Inc. |
RS-2023-00282595 |
|
| 3 |
Development of an sFasL-targeted antibody therapy for treating arthritis that is non-responsive or resistant to TNFα inhibitors |
| Antibody |
Rheumatoid Arthritis |
sFas L |
Hit |
Seoul National University |
RS-2023-00259272 |
|
| 4 |
IM.101: Complement Inhibitor for Autoimmune Diseases |
| Antibody |
Autoimmune diseases |
Human Complement C5 |
Phase 1 |
ImmunAbs |
RS-2023-00258444 |
|
| 5 |
Candidate selection for development of an immunosuppressive monoclonal antibody against allergic disease |
| Antibody |
Atopic dermatitis |
CD200R1 |
Candidate |
AIMEDBIO Inc. |
RS-2023-00218545 |
|
| 6 |
Novel antibody candidate for rheumatoid arthritis |
| Antibody |
Rheumatoid Arthritis |
WARS1 |
Candidate |
MirimGene |
RS-2022-00166575 |
|
| 7 |
Evaluation of drug efficacy and discovery of pharmacodynamics biomarkers of a new anti-CD40 antibody lead compound (PB101) for the treatment of Pemphigus, a rare intractable skin disease |
| Antibody |
Pemphigus |
CD40 |
Lead |
PB Immune Therapeutics |
RS-2022-00165917 |
|
| 8 |
Development of innovative monoclonal antibody drug targeting dimeric TCTP/HRF for treatment of chronic inflammatory diseases |
| Antibody |
Chronic Inflammatory diseases |
TCTP/HRF |
Lead |
Ewha Women's University |
HN22C0533 |
|
| 9 |
Multi-functional immune-modulating antibody therapeutics for autoimmune disease |
| Antibody |
Rheumatoid Arthritis, Autoimmune Disease |
OX40L, TNF-α |
Preclinical |
IMBiologics |
HN22C0229 |
|
| 10 |
Development of Complement C5-inhibiting antibody for Autoimmune diseases |
| Antibody |
Paroxysmal nocturnal hemoglobinuria |
C5 |
Preclinical |
ImmunAbs |
HN21C0649 |
|
| 11 |
Lead selection and optimization of therapeutic anti- CD40 antibody for the treatment of multiple sclerosis |
| Antibody |
Multiple Sclerosis |
CD40 |
Lead |
PB immune therapeutics |
HN21C1359 |
|
